The acquisition enhances PCI’s portfolio of molecule-to-market capabilities, adding sterile and non-sterile drug manufacturing services for early phase studies
The global biopharmaceutical outsourcing services provider PCI Pharma Services (PCI) has announced the completion of its acquisition of Sherpa Clinical Packaging (Sherpa).
Located in San Diego, Sherpa is a recognised provider of clinical trial material management services and is known for its high quality, flexibility, and speed-to-market in support of investigational studies conducted around the world.
Sherpa’s packaging, labeling, distribution, temperature-controlled storage and returns services are highly complementary to PCI and adding this key geography further strengthens PCI’s ability to support existing and new customers.
Sherpa’s state-of-the art facilities include primary and secondary packaging services coupled with cutting edge cold chain and ultra cold chain technologies.
PCI now has manufacturing and packaging facilities in eight key locations across three continents and an extensive depot network to service its customers’ global needs. San Diego joins PCI’s existing sites in Rockford, IL; Bridgend, UK; Dublin, Ireland; and Melbourne, Australia in supporting medicines with temperature requirements ranging from controlled room temperature 15-25°C, cold chain refrigerated storage, and ultra cold chain frozen requirements down to cryogenic temperatures of -196°C.
“PCI’s overarching tenet is to provide the industry leading customer experience,” said Salim Haffar, PCI CEO.
Haffar continued: “We evaluated the Sherpa business and found they share this passion, which is demonstrated by their impressive growth. Sherpa’s investments in its capabilities, capacity, and talent have contributed to a successful service model."
"The integration of the Sherpa business with PCI’s global suite of capabilities and strategic locations allows us to continue to provide a best-in-class offering and be an even stronger partner for our customers,” he said.